Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Malignant Lymphoma

  Free Subscription


Articles published in Am J Hematol

Retrieve available abstracts of 107 articles:
HTML format



Single Articles


    May 2020
  1. MONDELLO P, Musolino C, Dogliotti I, Bohn JP, et al
    ABVD vs BEACOPP escalated in Advanced-Stage Hodgkin's Lymphoma: results from a multicenter European study.
    Am J Hematol. 2020 May 17. doi: 10.1002/ajh.25871.
    PubMed     Abstract available


  2. ANSELL SM
    Hodgkin Lymphoma: 2020 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2020 May 8. doi: 10.1002/ajh.25856.
    PubMed     Abstract available


  3. JAIN P, Tang G, Li S, Wang M, et al
    "Triple Hit" SOX-11(-) , CD10(+) , TP53 mutated high-grade pleomorphic mantle cell lymphoma.
    Am J Hematol. 2020 May 1. doi: 10.1002/ajh.25848.
    PubMed    


    April 2020
  4. DHARMAVARAM G, Cao S, Sundaram S, Ayyapan S, et al
    Aggressive Lymphoma Subtype Is A Risk Factor for Venous Thrombosis. Development of Lymphoma - Specific Venous Thrombosis Prediction Models.
    Am J Hematol. 2020 Apr 20. doi: 10.1002/ajh.25837.
    PubMed     Abstract available


  5. CHOW VA, Rajendran JG, Fisher DR, Appelbaum FR, et al
    A Phase II Trial Evaluating The Efficacy of High-Dose Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide followed by Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25818.
    PubMed     Abstract available


  6. KEMPS PG, Cleven AHG, van Wezel T, van Eijk R, et al
    B-cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25801.
    PubMed    


  7. ZHAO S, Kanagal-Shamanna R, Navsaria L, Chi Young OK, et al
    Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
    Am J Hematol. 2020 Apr 2. doi: 10.1002/ajh.25796.
    PubMed     Abstract available


    March 2020
  8. EL CHAER F, Siegel A, Holtzman NG, Bukhari A, et al
    Severe Dysautonomia as a Manifestation of Neurotoxicity after CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma.
    Am J Hematol. 2020 Mar 31. doi: 10.1002/ajh.25794.
    PubMed    


  9. WASTERLID T, Harrysson S, Andersson TM, Ekberg S, et al
    Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma.
    Am J Hematol. 2020 Mar 17. doi: 10.1002/ajh.25789.
    PubMed     Abstract available


  10. KAPLAN LD, Maurer MJ, Stock W, Bartlett NL, et al
    Bortezomib Consolidation or Maintenance Following Immunochemotherapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: CALGB/Alliance 50403.
    Am J Hematol. 2020 Mar 13. doi: 10.1002/ajh.25783.
    PubMed     Abstract available


  11. ZANWAR S, Abeykoon JP, Durot E, King R, et al
    Impact of MYD88(L265P) mutation status on histological transformation of Waldenstrom Macroglobulinemia.
    Am J Hematol. 2020;95:274-281.
    PubMed     Abstract available


    February 2020
  12. BELTRAN BE, Castro D, Paredes S, Miranda RN, et al
    EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management.
    Am J Hematol. 2020 Feb 18. doi: 10.1002/ajh.25760.
    PubMed     Abstract available


  13. TIMMERMAN J, Herbaux C, Ribrag V, Zelenetz AD, et al
    Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
    Am J Hematol. 2020 Feb 13. doi: 10.1002/ajh.25757.
    PubMed     Abstract available


  14. FOSS FM, Horwitz SM, Civallero M, Bellei M, et al
    Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas.
    Am J Hematol. 2020;95:151-155.
    PubMed     Abstract available


    January 2020
  15. QASRAWI A, Arora R, Ramlal R, Munker R, et al
    Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
    Am J Hematol. 2020 Jan 9. doi: 10.1002/ajh.25725.
    PubMed    


    December 2019
  16. DREYLING M, Santoro A, Mollica L, Leppa S, et al
    Long-term safety and efficacy of the PI3K- inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
    Am J Hematol. 2019 Dec 23. doi: 10.1002/ajh.25711.
    PubMed     Abstract available


  17. OLSZEWSKI AJ, Butera JN, Reagan JL, Castillo JJ, et al
    Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma.
    Am J Hematol. 2019 Dec 17. doi: 10.1002/ajh.25707.
    PubMed     Abstract available


  18. PARSONS K, Leach M, Bain BJ
    Hodgkin lymphoma in a bone marrow aspirate.
    Am J Hematol. 2019 Dec 17. doi: 10.1002/ajh.25708.
    PubMed    


  19. FREEDMAN A, Jacobsen E
    Follicular lymphoma: 2019 update on diagnosis and management.
    Am J Hematol. 2019 Dec 8. doi: 10.1002/ajh.25696.
    PubMed     Abstract available


  20. QIAN L, Soderquist C, Schrank-Hacker A, Strauser H, et al
    Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma.
    Am J Hematol. 2019 Dec 5. doi: 10.1002/ajh.25694.
    PubMed     Abstract available


    November 2019
  21. RAYCHAUDHURI R, Qualtieri J, Garfall AL
    Axicabtagene Ciloleucel for CD19+ Plasmablastic Lymphoma.
    Am J Hematol. 2019 Nov 14. doi: 10.1002/ajh.25682.
    PubMed    



  22. Abstracts from the 2019 Lymphoma and Myeloma Congress October 23-26, 2019 New York, NY.
    Am J Hematol. 2019;94 Suppl 2:S3-S33.
    PubMed    


    October 2019
  23. ABDULLA M, Hollander P, Pandzic T, Mansouri L, et al
    Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.
    Am J Hematol. 2019 Oct 29. doi: 10.1002/ajh.25666.
    PubMed     Abstract available


  24. HERRERA AF, Goy A, Mehta A, Ramchandren R, et al
    Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
    Am J Hematol. 2019 Oct 17. doi: 10.1002/ajh.25659.
    PubMed     Abstract available


    September 2019
  25. MUNIR T, Brown JR, O'Brien S, Barrientos JC, et al
    Final analysis from RESONATE: up to 6 years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Am J Hematol. 2019 Sep 11. doi: 10.1002/ajh.25638.
    PubMed     Abstract available


  26. FLINN IW, Cherry MA, Maris MB, Matous JV, et al
    Combination Trial of Duvelisib (IPI-145) with Rituximab or Bendamustine/Rituximab in Patients with Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia.
    Am J Hematol. 2019 Sep 6. doi: 10.1002/ajh.25634.
    PubMed     Abstract available


  27. HRISTOV AC, Tejasvi T, Wilcox RA
    Mycosis fungoides and Sezary syndrome: 2019 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2019;94:1027-1041.
    PubMed     Abstract available


  28. HINTON R, Yebra-Fernandez E, Bain BJ
    Sezary syndrome: The cause of erythema revealed by the blood film.
    Am J Hematol. 2019;94:1042-1043.
    PubMed    


  29. PERRY C, Ben Barouch S, Goldschmidt N, Sarid N, et al
    Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.
    Am J Hematol. 2019;94:992-1001.
    PubMed     Abstract available


    August 2019
  30. DEOL A, Uberti J
    Rapid and Sustained Response to CAR T Cell Therapy in Double Hit Diffuse Large B Cell Lymphoma.
    Am J Hematol. 2019 Aug 19. doi: 10.1002/ajh.25621.
    PubMed    


  31. HARTMANN S, Plutschow A, Mottok A, Bernd HW, et al
    The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma.
    Am J Hematol. 2019 Aug 8. doi: 10.1002/ajh.25607.
    PubMed     Abstract available


  32. VARETTONI M, Boveri E, Zibellini S, Tedeschi A, et al
    Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: a multicentric study of the Rete Ematologica Lombarda (REL) network.
    Am J Hematol. 2019 Aug 4. doi: 10.1002/ajh.25600.
    PubMed     Abstract available


  33. ZAIN JM
    Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
    Am J Hematol. 2019;94:929-946.
    PubMed     Abstract available


  34. CHOW VA, Gopal AK, Maloney DG, Turtle CJ, et al
    Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
    Am J Hematol. 2019;94:E209-E213.
    PubMed    


    July 2019
  35. BUKHARI A, El Chaer F, Koka R, Singh Z, et al
    Rapid Relapse of Large B-Cell Lymphoma after CD19 Directed CAR-T-Cell Therapy due to CD-19 Antigen Loss.
    Am J Hematol. 2019 Jul 24. doi: 10.1002/ajh.25591.
    PubMed    


  36. BAIN BJ
    Pseudoplatelets and apoptosis in Burkitt lymphoma.
    Am J Hematol. 2019 Jul 24. doi: 10.1002/ajh.25586.
    PubMed    


  37. ARMAND M, Costopoulos M, Osman J, Tarfi S, et al
    Optimization of CSF biological investigations for CNS lymphoma diagnosis.
    Am J Hematol. 2019 Jul 21. doi: 10.1002/ajh.25578.
    PubMed     Abstract available


  38. RUMI E, Zibellini S, Boveri E, Cavalloni C, et al
    Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms.
    Am J Hematol. 2019;94:E185-E188.
    PubMed    


    June 2019
  39. KHARFAN-DABAJA MA, Jain MD, Aulakh S, Ayala E, et al
    Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells.
    Am J Hematol. 2019 Jun 18. doi: 10.1002/ajh.25560.
    PubMed    


  40. TRACY SI, Larson MC, Feldman AL, Maurer MJ, et al
    The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas.
    Am J Hematol. 2019;94:658-666.
    PubMed     Abstract available


    April 2019
  41. ST-PIERRE F, Broski SM, LaPlant BR, Ristow K, et al
    Detection of Extranodal and Spleen Involvement by FDG-PET Imaging Predicts Adverse Survival in Untreated Follicular Lymphoma.
    Am J Hematol. 2019 Apr 21. doi: 10.1002/ajh.25493.
    PubMed     Abstract available


  42. OUSEPH M, Pinkus GS, Dorfman DM
    Pleomorphic mantle cell lymphoma mimicking diffuse large B cell lymphoma in peripheral blood and bone marrow.
    Am J Hematol. 2019 Apr 20. doi: 10.1002/ajh.25491.
    PubMed    


  43. JAIN P, Wang M
    Mantle Cell Lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication and management.
    Am J Hematol. 2019 Apr 8. doi: 10.1002/ajh.25487.
    PubMed     Abstract available


  44. ISIDORI A, Loscocco F, Guiducci B, Visani G, et al
    Benda-EAM prior to ASCT and renal toxicity: Much ado about nothing.
    Am J Hematol. 2019;94:E104-E105.
    PubMed    


  45. CHANTEPIE S, Yakoub-Agha I, Damaj G
    Be ever cautious until the truth is proven.
    Am J Hematol. 2019;94:E106.
    PubMed    


  46. SMITH SD, Reddy P, Sokolova A, Chow VA, et al
    Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL.
    Am J Hematol. 2019;94:E117-E116.
    PubMed    


  47. HAMLIN PA, Flinn IW, Wagner-Johnston N, Burger JA, et al
    Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
    Am J Hematol. 2019;94:E90-E93.
    PubMed    


    March 2019
  48. STUVER RN, Khan N, Schwartz M, Acosta M, et al
    Single Agents Versus Combination Chemotherapy in Relapsed and Refractory Peripheral T-cell Lymphoma: Results from the Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) Registry.
    Am J Hematol. 2019 Mar 21. doi: 10.1002/ajh.25463.
    PubMed     Abstract available


  49. LIU Y, Barta SK
    Diffuse Large B cell Lymphoma: 2019 update on diagnosis, risk-stratification and treatment.
    Am J Hematol. 2019 Mar 11. doi: 10.1002/ajh.25460.
    PubMed     Abstract available


  50. MAURA F, Agnelli L, Leongamornlert D, Bolli N, et al
    Integration of Transcriptional and Mutational Data Simplifies the Stratification of Peripheral T-Cell Lymphoma.
    Am J Hematol. 2019 Mar 4. doi: 10.1002/ajh.25450.
    PubMed     Abstract available


  51. FURUTANI E, Newburger PE, Shimamura A
    Neutropenia in the age of genetic testing: Advances and challenges.
    Am J Hematol. 2019;94:384-393.
    PubMed     Abstract available


    February 2019
  52. WANG Y, Habermann TM, Wang SS, Maurer MJ, et al
    Host Genetic Variation in the TNF and NF-kB Pathways and Overall Survival in Mantle Cell Lymphoma: A Discovery and Replication Study.
    Am J Hematol. 2019 Feb 27. doi: 10.1002/ajh.25451.
    PubMed    


  53. STRATI P, Lee ST, Teegavarupu P, Karri A, et al
    Frontline Antibiotic Therapy for Early Stage Helicobacter Pylori Negative Gastric MALT Lymphoma.
    Am J Hematol. 2019 Feb 20. doi: 10.1002/ajh.25447.
    PubMed    


  54. ALDERUCCIO JP, Zhao W, Desai A, Ramdial J, et al
    Short Survival and Frequent Transformation in Extranodal Marginal Zone Lymphoma with Multiple Mucosal Sites Presentation.
    Am J Hematol. 2019 Feb 19. doi: 10.1002/ajh.25446.
    PubMed     Abstract available


  55. SAWAYAMA Y, Itonaga H, Fukushima T, Nakano N, et al
    Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma.
    Am J Hematol. 2019 Feb 17. doi: 10.1002/ajh.25438.
    PubMed    


  56. ARORA N, Eule C, Gupta A, Li HC, et al
    Clinicopathologic Features, Management and Outcomes of Plasmablastic Lymphoma: A Ten-Year Experience.
    Am J Hematol. 2019 Feb 7. doi: 10.1002/ajh.25432.
    PubMed    


  57. LUCIJANIC M, Prka Z, Jaksic O, Mitrovic Z, et al
    Bendamustine-based conditioning prior to autologous stem cell transplantation is associated with high rate of febrile neutropenia and higher mortality.
    Am J Hematol. 2019;94:E42-E43.
    PubMed    


    January 2019
  58. HONG H, Huang H, Fang X, Wang Z, et al
    A prognostic index for nasal-type early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
    Am J Hematol. 2019 Jan 28. doi: 10.1002/ajh.25426.
    PubMed    


  59. DE LA FUENTE MI, Alderuccio JP, Reis IM, Omuro A, et al
    Bilateral Radiation Therapy followed by Methotrexate-based Chemotherapy for Primary Vitreoretinal Lymphoma.
    Am J Hematol. 2019 Jan 21. doi: 10.1002/ajh.25414.
    PubMed     Abstract available


    December 2018
  60. CASTELLINO A, Pulido JS, Johnston PB, Ristow KM, et al
    Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.
    Am J Hematol. 2018 Dec 5. doi: 10.1002/ajh.25350.
    PubMed     Abstract available


    November 2018
  61. MACKRIDES N, Chapman J, Larson MC, Ramos JC, et al
    Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma.
    Am J Hematol. 2018 Nov 25. doi: 10.1002/ajh.25357.
    PubMed    


  62. KLENER P, Salek D, Pytlik R, Mocikova H, et al
    Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.
    Am J Hematol. 2018 Nov 25. doi: 10.1002/ajh.25362.
    PubMed     Abstract available


    October 2018
  63. WONG WJ, Ruhangaza D, Manirakiza A, Omondi J, et al
    Concomitant Classic Hodgkin Lymphoma and Schistosomiasis.
    Am J Hematol. 2018 Oct 17. doi: 10.1002/ajh.25316.
    PubMed    


    September 2018
  64. POPHALI PA, Ip A, Larson MC, Rosenthal AC, et al
    The Association of Physical Activity Before and After Lymphoma Diagnosis with Survival Outcomes.
    Am J Hematol. 2018 Sep 19. doi: 10.1002/ajh.25288.
    PubMed     Abstract available


  65. TISI MC, Paolini R, Piazza F, Ravelli E, et al
    Rituximab, Bendamustine and Cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.
    Am J Hematol. 2018 Sep 5. doi: 10.1002/ajh.25278.
    PubMed    


    August 2018
  66. O'BRIEN S, Patel M, Kahl BS, Horwitz SM, et al
    Duvelisib, an oral dual PI3K-delta,gamma inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a Phase 1 study.
    Am J Hematol. 2018 Aug 10. doi: 10.1002/ajh.25243.
    PubMed     Abstract available


  67. BAIN BJ, Branislav C
    Monocyte adhesion with platelet satellitism and phagocytosis in Hodgkin lymphoma.
    Am J Hematol. 2018 Aug 3. doi: 10.1002/ajh.25241.
    PubMed     Abstract available


    July 2018
  68. SIEGEL SE, Advani A, Seibel N, Muffly L, et al
    Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD versus pediatric-inspired regimens.
    Am J Hematol. 2018 Jul 30. doi: 10.1002/ajh.25229.
    PubMed     Abstract available


  69. SIOW W, Burton K, Eagleton H, Campbell C, et al
    Transformation of follicular lymphoma.
    Am J Hematol. 2018 Jul 24. doi: 10.1002/ajh.25195.
    PubMed    


  70. HILAL T, Wang Z, Almader-Douglas D, Rosenthal A, et al
    Rituximab Maintenance Therapy for Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Am J Hematol. 2018 Jul 23. doi: 10.1002/ajh.25226.
    PubMed     Abstract available


  71. FLINN IW, Patel M, Oki Y, Horwitz S, et al
    Duvelisib, an Oral Dual PI3K-delta, gamma Inhibitor, Shows Clinical Activity in Indolent Non-Hodgkin Lymphoma in a Phase 1 Study.
    Am J Hematol. 2018 Jul 22. doi: 10.1002/ajh.25228.
    PubMed     Abstract available


  72. CASTILLO JJ, Beltran BE, Miranda RN, Young KH, et al
    EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management.
    Am J Hematol. 2018;93:953-962.
    PubMed     Abstract available


    June 2018
  73. BAIN BJ
    Diagnosis of follicular lymphoma from the peripheral blood.
    Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25158.
    PubMed    


  74. ROSSI C, Gilhodes J, Maerevoet M, Herbaux C, et al
    Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.
    Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154.
    PubMed     Abstract available


    May 2018
  75. EKBERG S, Jerkeman M, Andersson PO, Enblad G, et al
    Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma.
    Am J Hematol. 2018 May 17. doi: 10.1002/ajh.25147.
    PubMed     Abstract available


  76. PATEL S, Li Y, Berchuck JE, Cunningham J, et al
    Did you 'miss' me? A subtle case of intravascular large B-cell lymphoma.
    Am J Hematol. 2018 May 13. doi: 10.1002/ajh.25132.
    PubMed    


  77. ANSELL SM
    Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2018;93:704-715.
    PubMed     Abstract available


    April 2018
  78. SIEGELE BJ, Nardi V
    Laboratory Testing in BCR-ABL1-like (Philadelphia-like) B-Lymphoblastic Leukemia/Lymphoma.
    Am J Hematol. 2018 Apr 26. doi: 10.1002/ajh.25126.
    PubMed     Abstract available


  79. PARDAL E, Diez Baeza E, Salas Q, Garcia T, et al
    Which very elderly diffuse large B-cell lymphoma patients can benefit from curative treatment? A multicenter, retrospective analysis by the Spanish GELTAMO group.
    Am J Hematol. 2018 Apr 15. doi: 10.1002/ajh.25107.
    PubMed     Abstract available


    February 2018
  80. CHANTEPIE SP, Garciaz S, Tchernonog E, Peyrade F, et al
    Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.
    Am J Hematol. 2018 Feb 23. doi: 10.1002/ajh.25077.
    PubMed     Abstract available


  81. CARBONE A, Gloghini A
    Current and potential use of pathological targets in the treatment of Hodgkin lymphoma.
    Am J Hematol. 2018 Feb 2. doi: 10.1002/ajh.25054.
    PubMed    


  82. FREEDMAN A
    Follicular lymphoma: 2018 update on diagnosis and management.
    Am J Hematol. 2018;93:296-305.
    PubMed     Abstract available


    January 2018
  83. OLSZEWSKI AJ, Reagan JL, Castillo JJ
    Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas.
    Am J Hematol. 2018;93:E1-E3.
    PubMed    


    December 2017
  84. PERSKY DO, Li H, Rimsza LM, Barr PM, et al
    A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806.
    Am J Hematol. 2017 Dec 20. doi: 10.1002/ajh.25010.
    PubMed     Abstract available


  85. BOONSTRA PS, Polk A, Brown N, Hristov AC, et al
    A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.
    Am J Hematol. 2017;92:1287-1294.
    PubMed     Abstract available


    November 2017
  86. RIBES D, El Hachem H, Oberic L, Vergez F, et al
    Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.
    Am J Hematol. 2017 Nov 23. doi: 10.1002/ajh.24984.
    PubMed     Abstract available


  87. XAVIER AC, Epperla N, Taub JW, Costa LJ, et al
    Excess Mortality Among Ten-Year Survivors of Classical Hodgkin Lymphoma in Adolescents and Young Adults.
    Am J Hematol. 2017 Nov 8. doi: 10.1002/ajh.24964.
    PubMed     Abstract available


    October 2017
  88. ABAZA Y, Kantarjian HM, Faderl S, Jabbour E, et al
    Hyper-CVAD plus Nelarabine in Newly Diagnosed Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma.
    Am J Hematol. 2017 Oct 19. doi: 10.1002/ajh.24947.
    PubMed     Abstract available


  89. AKHTAR S, Montoto S, Boumendil A, Finel H, et al
    High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European Society for Blood and Marrow Transplantation (EBMT)-Lymphoma Working Party.
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24927.
    PubMed     Abstract available


  90. WILCOX RA
    Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2017;92:1085-1102.
    PubMed     Abstract available


  91. LOMBARDI A, Croci GA, Brazzelli V, Vecchia M, et al
    Cutaneous septic emboli from Candida glabrata in a haematological patient.
    Am J Hematol. 2017;92:1111-1112.
    PubMed    


    September 2017
  92. BELETE H, Burns LJ, Shanley R, Nayar M, et al
    Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients.
    Am J Hematol. 2017;92:E529-E533.
    PubMed     Abstract available


  93. BEHRENS M, Chowdry RP, Saba S, Saba NS, et al
    A centrocyte blood count of a quarter million.
    Am J Hematol. 2017;92:972-973.
    PubMed    


    August 2017
  94. VOSE JM
    Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
    Am J Hematol. 2017;92:806-813.
    PubMed     Abstract available


    July 2017
  95. MALECEK MK, Petrich AM, Rozell S, Chu B, et al
    Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated with Dose-Adjusted EPOCH plus Rituximab.
    Am J Hematol. 2017 Jul 18. doi: 10.1002/ajh.24864.
    PubMed     Abstract available


  96. WITZIG TE, Zinzani PL, Habermann TM, Tuscano JM, et al
    Long-Term Analysis of Phase II Studies of Single-Agent Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma.
    Am J Hematol. 2017 Jul 11. doi: 10.1002/ajh.24854.
    PubMed     Abstract available


  97. ARMITAGE JO
    The aggressive peripheral T-cell lymphomas: 2017.
    Am J Hematol. 2017;92:706-715.
    PubMed     Abstract available


    June 2017
  98. JAIN P, Kantarjian H, Jain N, Short NJ, et al
    Clinical characteristics and outcomes of previously untreated patients with adult onset T-ALL and T-lymphoblastic lymphoma (T-LL) with Hyper-CVAD based regimens.
    Am J Hematol. 2017 Jun 24. doi: 10.1002/ajh.24833.
    PubMed    


  99. WITZIG TE, Johnston PB, LaPlant BR, Kurtin PJ, et al
    Long-term Follow-up of Chemoimmunotherapy with Rituximab, Oxaliplatin, Cytosine Arabinoside, Dexamethasone (ROAD) in Patients With Relapsed CD20+ B-Cell Non-Hodgkin Lymphoma: Results of a study of the Mayo Clinic Cancer Research Consortium (MCCRC) MC0
    Am J Hematol. 2017 Jun 14. doi: 10.1002/ajh.24824.
    PubMed     Abstract available


  100. SAYGIN C, Jia X, Hill B, Dean R, et al
    Impact of Comorbidities on Outcomes of Elderly Patients with Diffuse Large B-cell Lymphoma.
    Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24819.
    PubMed     Abstract available


  101. LANZA F, Saraceni F, Pezzi A, Martino M, et al
    A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach.
    Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24817.
    PubMed    


    May 2017
  102. HELBER MJ, Moore JE, Williams AM, Meacham PJ, et al
    Ibrutinib Therapy for Lymphoplasmacytic Lymphoma.
    Am J Hematol. 2017 May 24. doi: 10.1002/ajh.24795.
    PubMed    


  103. BAIR SM, Strelec L, Nagle SJ, Nasta SD, et al
    Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.
    Am J Hematol. 2017 May 16. doi: 10.1002/ajh.24792.
    PubMed     Abstract available


    April 2017
  104. BINDER M, O'Byrne MM, Maurer MJ, Ansell S, et al
    Associations between Elevated Pre-treatment Serum Cytokines and Peripheral Blood Cellular Markers of Immunosuppression in Patients with Lymphoma.
    Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24758.
    PubMed     Abstract available


  105. HANSEN JW, Garde C, Asmar F, Tholstrup D, et al
    Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma.
    Am J Hematol. 2017 Apr 5. doi: 10.1002/ajh.24751.
    PubMed     Abstract available


    March 2017
  106. MAJOR A, Pan Z, Kamdar M
    Secondary CNS Involvement of ALK-Negative Anaplastic Large Cell Lymphoma.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24733.
    PubMed    


    January 2017
  107. RIZZO D, Viailly PJ, Mareschal S, Bohers E, et al
    Oncogenic events rather than antigen selection pressure may be the main driving forces for relapse in diffuse large B-cell lymphomas.
    Am J Hematol. 2017;92:68-76.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: